Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
Pierre Gourdy, Patrice Darmon, François Diévart, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Saleh Hadi Alharbi
Therapeutic Advances in Endocrinology and Metabolism (2024) Vol. 15
Open Access | Times Cited: 70
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes
Raffaele Marfella, Francesco Prattichizzo, Celestino Sardu, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Diagnosis and management of type 2 diabetes mellitus in patients with ischaemic heart disease and acute coronary syndromes - a review of evidence and recommendations
Muhammad Usman Shah, Alun Roebuck, Bala Srinivasan, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access | Times Cited: 4
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Irene Caruso, Ludovico Di Gioia, Sergio Di Molfetta, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102181-102181
Open Access | Times Cited: 25
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies
Aftab Ahmad, Hani Sabbour
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Once-Weekly Insulin: A Breakthrough in Diabetes Management or an Unresolved Challenge?
Raheel Ahmed, Aimen Shafiq, Mushood Ahmed
British Journal of Hospital Medicine (2025), pp. 1-6
Closed Access | Times Cited: 1
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes
Receptors (2025) Vol. 4, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A propensity score-matched cohort study
Tao Liu, Zeyuan Fan, Yuntao Li, et al.
International Journal of Cardiology (2025), pp. 133229-133229
Open Access | Times Cited: 1
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
Kosuke Sawami, Atsushi Tanaka, Koichi Node
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
John W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan
European Heart Journal (2024) Vol. 45, Iss. 30, pp. 2748-2751
Closed Access | Times Cited: 7
Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism—A Narrative Review
Zsolt Szekeres, András Nagy, K. Jahner, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8214-8214
Open Access | Times Cited: 7
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
André Scheen
Drugs (2024)
Closed Access | Times Cited: 7
Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
Guillaume Mahé, Victor Aboyans, E. Cosson, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines
Pierre Gourdy, François Schiele, Jean‐Michel Halimi, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 12
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared With Monotherapy Improves Long-Term Survival: A Real-World Registry
David García‐Vega, Sergio Cinza‐Sanjurjo, Sonia Eirás, et al.
The American Journal of Medicine (2024) Vol. 137, Iss. 8, pp. 761-769.e1
Closed Access | Times Cited: 4
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile
André Scheen
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 797-810
Closed Access | Times Cited: 4
Bioengineered Nanomedicines Targeting the Intestinal Fc Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model
Soraia Pinto, Juliana Santos Rosa Viegas, Cecília Cristelo, et al.
ACS Nano (2024) Vol. 18, Iss. 41, pp. 28406-28424
Closed Access | Times Cited: 4
Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review
Ming Xu, Dongqing Lv, Hongxia Wei, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Combination Therapy of SGLT 2 Inhibitors and GLP 1 Receptor Agonists for Glycaemic Management through Weight Reduction
Vinod Kumar, V B Amulya, Manjari Sharma, et al.
Journal of Drug Delivery and Therapeutics (2025) Vol. 15, Iss. 1, pp. 142-148
Open Access
Efficacy and safety of traditional Chinese medicine and SGLT2i, GLP‐1RA, and ACEI/ARB in the management of diabetic kidney disease: A systematic review and network meta‐analysis
Jiarong Liu, Jixiong Xu
Rheumatology & autoimmunity (2025)
Open Access
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on glycemic variability, islet cell function, and insulin resistance in patients with type 2 diabetes mellitus and renal cell carcinoma
Anqi Zhang, Xincheng Zhang, Aige Yang, et al.
American Journal of Cancer Research (2025) Vol. 15, Iss. 3, pp. 946-965
Closed Access
The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy
Elena Crecca, Gianfranco Di Giuseppe, C Camplone, et al.
Pharmacology & Therapeutics (2025), pp. 108847-108847
Closed Access
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
Maria Elena Lunati, Vincenzo Cimino, Davide Paolo Bernasconi, et al.
Pharmacological Research (2023) Vol. 199, pp. 107040-107040
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top